Catalyst

Slingshot members are tracking this event:

Phase 3 data of HyperAcute Pancreas - IMPRESS trial for Surgically resected pancreatic cancer due 2016

Source Link:
http://investors.linkp.com/releasedetail.cfm?ReleaseID=940024

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NLNK Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Algenpantucel-L is NewLink Genetics' HyperAcute Cellular Immunotherapy product candidate for patients with pancreatic cancer. The product is currently being studied in a Phase 3 clinical trial called IMPRESS, or IMmunotherapy for Pancreatic RESectable Cancer Study, in patients with surgically resected pancreatic cancer. The study is powered to show an improvement in overall survival after 442 events, and we continue to expect that final results will be reported in 2016.
http://investors.lin...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 09, 2016
Occurred Source:
http://investors.linkp.com/releasedetail.cfm?releaseid=969978
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Hyperacute Pancreas, Impress Trial, Surgically Resected Pancreatic Cancer
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.